SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing intense volatility as investors closely monitor geopolitical escalations in the Middle East, specifically threats surrounding the Strait of Hormuz and potential impacts on global energy supply chains. Market participants are actively debating the sustainability of current tech valuations and discussing whether the recent pullbacks represent a strategic buying opportunity or the beginning of a deeper market correction driven by macroeconomic uncertainty.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Gold is facing a sharp sell-off as a combination of a surging dollar, rising interest rate expectations, and broader liquidity concerns drives investors to exit precious metal positions. The community is actively debating whether this is a temporary shakeout that offers a buying opportunity for long-term holders or a more systemic shift that challenges gold's status as a traditional safe-haven asset during times of geopolitical tension.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is currently trending as investors grapple with extreme market volatility driven by escalating geopolitical tensions in the Middle East and the uncertainty surrounding impending policy deadlines. The community is sharply divided, with intense debate focused on whether these conditions signal an imminent market collapse or a temporary shakeout that will ultimately favor opportunistic buyers.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is experiencing significant volatility as market participants react to intensifying geopolitical tensions in the Middle East and the company's involvement in broader national political discourse. Investors and community members are actively debating the potential economic impact of these escalations, with sentiment heavily divided between those betting on stock recovery and those expressing concerns over the firm's long-term stability.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is facing significant downward pressure as investors weigh a contentious short report from Muddy Waters against recent insider buying from CEO Anthony Noto. The community remains deeply polarized, with some traders bracing for further volatility amid broader market concerns while others view the current price as a buying opportunity based on the company's long-term growth potential.

Direxion Shares ETF Trust - Direxion Daily Junior Gold Miners Index Bull 2X ETF

Direxion Daily Junior Gold Miners Index Bull 2X Shares

JNUG is trending as investors weigh the impact of rising geopolitical tensions and inflationary pressures on the junior gold miners sector. Community sentiment remains split between bullish bets on gold as a hedge against systemic risk and bearish warnings about the volatility and leverage inherent in the instrument.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund ($USO) is trending as energy markets react to intensifying geopolitical volatility in the Middle East, specifically driven by the U.S. ultimatum regarding the Strait of Hormuz and potential ground operations involving Kharg Island. Investors and community members are actively debating the potential for a severe supply shock against the backdrop of rising Treasury yields and shifting Fed expectations, while social media sentiment reflects a mix of skepticism regarding official military 'winding down' narratives and concerns over the inflationary impact of elevated energy prices.

Meet Soyjak. Soyjak, a portmanteau of "soy" and "wojak", is a variation of Wojak that combines Wojak-style illustrations with additional features to allude to a soy boy, such as a gaping "cuckface" with an excited expression, glasses, stubble, and a balding head.  Launched stealth with presale, zero taxes, LP burnt and contract renounced.  Soyjak is more than a token it's a movement to embrace the underdog in all of us and transform setbacks into comebacks!  Soyjak.party, (or just "The party") is an imageboard dedicated to the creation, posting, and sharing of soyjaks. As the site has grown, its expanded to encompass many other topics as well. Please read the rules before posting. Serving 9,462,739 posts!

Soyjak

The SOY symbol is facing heightened volatility and intense investor debate as market participants weigh geopolitical instability, ongoing tariff threats, and the potential impact of upcoming domestic policy shifts. Discussions are heavily focused on navigating macroeconomic pressures, with traders actively monitoring technical chart patterns and shifting institutional sentiment amidst the broader market turbulence.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing intense downward pressure and widespread investor frustration as the stock continues to hit fresh lows, significantly underperforming the broader market. The community is actively debating whether this represents a generational buying opportunity at these levels or if the stock is trapped in a prolonged structural decline driven by macro headwinds, geopolitical tensions, and skepticism surrounding the durability of AI-driven capital expenditures.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending after announcing a major partnership with Uber, which includes a significant capital investment and plans to deploy up to 50,000 autonomous R2 robotaxis by 2031. Community discussion remains heavily polarized between bulls, who view the deal as strong validation of Rivians long-term autonomous technology roadmap, and bears, who remain focused on the company's persistent cash burn and the long-term nature of these delivery milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the firm, Marketbeat Ratings reports. One...

Promising Biotech Stocks To Keep An Eye On - March 21st

Danaher, Vertex Pharmaceuticals, Moderna, United Therapeutics, ImmunityBio, argenex, and Medpace are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

ImmunityBio (NASDAQ:IBRX) Stock Price Down 4%  - Should You Sell?

ImmunityBio (NASDAQ:IBRX) Trading Down 4% - Time to Sell...

ImmunityBio Sees Unusually High Options Volume (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the recipient of unusually large options trading on Friday. Investors acquired 51,571 call options on the stock. This is an increase of 50...

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA in BCG-Unresponsive NMIBC with CIS Papillary Tumors

ImmunityBio, Inc. (NASDAQ: IBRX), today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the Peoples Republic of China has granted...

<ul class="summary-bullets"><li>A record $5.7 trillion “triple witching” options expiry threatens to inject fresh swings into an already fragile market.</li><li>Markets remain on edge as escalating Middle East tensions fuel oil volatility.</li><li>SMCI stock tanks 20% in early pre-market trade on alleged Nvidia chip diversion to China.&nbsp;</li></ul>U.S. stock futures took a breather early Friday with investors parsing the latest developments in the Middle East. However, fresh Israeli strikes on Iran and risks around the Strait of Hormuz are keeping oil volatility in action.Traders will also be&nbsp; focusing on a historic options expiration. They are&nbsp; bracing for a staggering $5.7 trillion in notional options to expire today, which is reportedly the largest March expiry in Citigroup data going back to 1996.&nbsp; As of 4:00 a.m. ET on Friday, Dow futures rose 0.2%, S&amp;P futures gained 0.1%, the Nasdaq futures were flat with a positive bias, and Russell 2000 futures were up 0.3%.Caution prevails among the traders. Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, remained ‘extremely bearish, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has remained ‘bearish’ amid high trading volume.&nbsp;Trending Stocks To Watch Super Micro Computer (SMCI):&nbsp;The stock is on retail radar this morning after U.S. prosecutors charged three individuals, including a co-founder and a board member, in a scheme to smuggle Nvidia (NVDA) chips to China. Both companies have stressed on compliance in their statements.&nbsp;Nvidia (NVDA) &amp; Amazon (AMZN):&nbsp;Despite the SMCI scandal, Nvidia remains in focus following reports it will sell 1 million chips to Amazon by the end of 2027 as part of a massive cloud infrastructure deal. Amazon also boosted its logistics wing by acquiring the autonomous robotics startup Rivr.Meta (META): The company reportedly reversed its decision to shut down&nbsp;Horizon Worlds for Quest VR headsets, citing fan feedback.Tech stocks also remain in the spotlight on reports that the White House is expected to release a&nbsp;national AI regulatory framework in the coming days.&nbsp;Tesla (TSLA):&nbsp;The EV giant is back in focus as it doubles down on its solar and energy ambitions with a $2.9 billion China-linked expansion, while also nearing a potential rollout of its Full Self-Driving (FSD) software in Europe.FedEx (FDX): The stock is garnering retail attention following a Q3 earnings beat and a raised FY26 outlook. Analysts at Wells Fargo and JPMorgan raised price targets to $430–$432.&nbsp;Investors are shifting focus to&nbsp;rare earth stocks (MP, UAMY, USAR) following a landmark joint action plan between the U.S. and Japan. The two nations announced a $73 billion energy and minerals initiative, including the development of deep-sea rare earth muds near Minamitori Island.&nbsp;Azitra Inc. (AZTR):&nbsp;The stock is seeing strong pre-market action following the pricing of a $31.4 million private placement financing.ImmunityBio, Inc. (IBRX): Its cancer therapy Anktiva appeared on Macau’s latest drug list. Also, the founder has flagged early immune activation data from an Anktiva study.Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included Firefly Aerospace (FLY), AppLovin Corp (APP), and Qualcom (QCOM).&nbsp;On earnings radar, watch out for quarterly reports from Milestone Scientific (MIST), XPeng (XPEV), and Zegna (ZGN) before the bell today.For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Take A Breather Ahead Of Massive Options Expiry: Why SMCI, NVDA, TSLA, UAMY, IBRX Are Keeping Traders Engaged Today

Data from Stocktwits indicated that retail sentiment remains bearish on SPY and QQQ. 

Equity

Data from Stocktwits indicated that retail sentiment remains bearish on SPY and QQQ. 


<ul class="summary-bullets"><li>Executive chairman Patrick Soon-Shiong highlighted early immune activation data from an Anktiva study.</li><li>Anktiva was also added to Macau’s drug list and included in updated NCCN guidelines for papillary bladder cancer.</li><li>ImmunityBio has resubmitted its FDA application for label expansion, while advancing lung cancer trials and expanding global approvals.</li></ul>Shares of ImmunityBio, Inc. (IBRX) posted modest gains in premarket trading on Friday after executive chairman and founder Patrick Soon-Shiong flagged early immune data from an Anktiva study, adding to momentum from recent regulatory and global developments.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained over 5% this week, snapping a two-week losing streak that had erased nearly 15% of its value.<h2 class="st-heading-2">Early Anktiva Data Shows Immune Activation</h2>Soon-Shiong said in a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2034892413802545271">post on X</a> that initial analysis from the first 20 subjects showed immune activation with Anktiva in combination with the company’s adenovirus-based cancer vaccine. The trial has enrolled 138 patients randomized to the combination or placebo. Data generated by the U.S. National Cancer Institute team showed confirmation of Anktiva’s immune-stimulating effect on absolute lymphocyte count.He added that baseline lymphocyte levels decline with age but appear to increase with Anktiva, citing research linking low levels to reduced lifespan. Soon-Shion also added that cancer vaccine trials are ongoing.<h2 class="st-heading-2">Anktiva Gains Macau Listing, NCCN Backing</h2>The update comes as Anktiva was added to Macau’s latest&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-snap-losing-streak-anktiva-macau-drug-list/cZ3XLBrRIhU">approved drug</a> list as a bladder cancer treatment. The inclusion places it alongside therapies from Bristol Myers Squibb, Eli Lilly, Vertex Pharmaceuticals, Gilead Sciences and Moderna.In the U.S., the National Comprehensive Cancer Network (NCCN) added Anktiva with BCG as an “other recommended” option for papillary bladder cancer that no longer responds to BCG, expanding its use beyond carcinoma in situ.<h2 class="st-heading-2">Anktiva Pipeline Expands With Strong Data</h2>ImmunityBio has resubmitted its application to expand Anktiva’s label to papillary bladder cancer after a prior refusal-to-file. In the Phase 2/3 Quilt 3.032 study, 58.2% of patients remained cancer-free at 12 months, while more than 80% avoided bladder removal surgery over three years, according to the company.The therapy is also being studied in lung cancer, with two pivotal trials underway, and has received authorizations in the U.K., Europe and Saudi Arabia.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX slid to ‘bearish’ from the ‘extremely bullish’ zone over the past three months amid over a 300% surge in message volumes over the same period.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_ba9f17d55e.webp" alt="ibrx ss.png" width="963" height="143"><figcaption>IBRX sentiment and message volume as of March 20 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/ActionCuresFear/message/648063131">said</a>, The market prices a bladder cancer drug. NCI just showed data proving it works on immune decline in people without cancer.”<stembedurl>https://stocktwits.com/ActionCuresFear/message/648063131</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Adi121/message/648063344">said</a>, “Anktiva is heading towards becoming universal cancer vaccine! Lynch syndrome is the proof of concept!”<stembedurl>https://stocktwits.com/Adi121/message/648063344</stembedurl>IBRX stock has more than tripled over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dr. Patrick Soon-Shiong arrives at Trump National Golf Club Bedminster in Bedminster Township, N.J. on Saturday, Nov. 19, 2016. (Photo by Jabin Botsford/The Washington Post via Getty Images)

IBRX Stock Rises Premarket As Founder Flags Early Anktiva Immune Data — Macau Nod Fuels Bull Case

 Early trial data showed immune activation in initial patients, with Anktiva boosting lymphocyte levels.

<ul class="summary-bullets"><li>The therapy also gained momentum in the U.S. after NCCN added it as a treatment option for papillary bladder cancer patients unresponsive to BCG.</li><li>ImmunityBio has resubmitted its FDA application to expand Anktiva’s use, backed by clinical data showing strong cancer-free and bladder preservation rates.</li><li>The company is advancing Anktiva globally, with lung cancer trials underway and recent approvals in markets including Saudi Arabia.</li></ul>Shares of ImmunityBio, Inc. (IBRX) are set to snap a two-week losing streak after its cancer therapy Anktiva appeared on Macau’s latest drug list, adding to fresh momentum from a U.S. guideline expansion.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained over 5% this week, snapping a two-week losing streak that had erased nearly 15% of its value.<h2 class="st-heading-2">Anktiva Added To Macau Approved List</h2>Anktiva, which is available under the generic name Nogapendekin alfa, is an immunotherapy that helps activate the body’s immune system to better fight cancer. It is approved in the U.S. for use with standard BCG treatment in patients with a type of bladder cancer that no longer responds to BCG, including those with or without certain tumor growths.The Macau filing, with data as of March, lists Anktiva as a bladder cancer treatment, identifying Nogapendekin alfa as its active ingredient and noting it is given as an injection for bladder cancer. The list also includes therapies approved by regulators such as the U.S. Food and Drug Administration (FDA), China’s National Medical Products Administration (NMPA), and the European Medicines Agency (EMA).Anktiva’s inclusion places it alongside a roster of globally approved therapies from major drugmakers, including Bristol Myers Squibb, Eli Lilly, Vertex Pharmaceuticals, Janssen, Gilead Sciences, and Moderna, positioning it among established treatments across oncology and specialty care.<h2 class="st-heading-2">NCCN Expansion Adds To Momentum</h2>The Macau development comes in the same week that Anktiva was added to updated U.S. treatment guidelines. The National Comprehensive Cancer Network (NCCN) added Anktiva, used with BCG, as an “other recommended” option for patients with papillary bladder cancer that no longer responds to BCG and has not spread into muscle tissue.Earlier versions of the guidelines had included the therapy only for carcinoma in situ. The update expands the potential patient population under clinical guidance, even as the indication is not yet formally approved by the FDA.<h2 class="st-heading-2">Anktiva Seeks Label Expansion</h2>ImmunityBio is seeking to expand Anktiva’s label to include papillary bladder cancer and has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-declines-immunitybio-resubmits-anktiva-application-to-fda/cZdVj9URIIL">resubmitted</a> its supplemental biologics license application to the FDA after previously receiving a refusal-to-file letter. The filing includes additional data requested by the agency, including updated efficacy results and long-term follow-up.Clinical data from the Phase 2/3 Quilt 3.032 study showed that 58.2% of patients remained cancer-free at 12 months, while more than 80% avoided bladder removal surgery over a three-year follow-up period, according to the company.<h2 class="st-heading-2">Global Push For Anktiva Grows</h2>Beyond bladder cancer, ImmunityBio is advancing Anktiva in lung cancer, with two pivotal trials underway in first-line and second-line non-small cell lung cancer. The company said multiple countries have expressed interest in the program as it explores broader regulatory pathways.The therapy has already received authorizations in the U.K., Europe and Saudi Arabia. In January, Saudi regulators granted approvals covering both bladder cancer and metastatic non-small cell lung cancer, including use in combination with checkpoint inhibitors.ImmunityBio said product shipments are ready to begin for a Saudi launch of Anktiva for bladder cancer, following regulatory approvals, and that it has partnered with regional distributors to expand access across the Middle East and North Africa.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX slid to ‘bearish’ from the ‘extremely bullish’ zone over the past three months amid over a 300% surge in message volumes over the same period.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_ba9f17d55e.webp" alt="ibrx ss.png" width="963" height="143"><figcaption>IBRX sentiment and message volume as of March 20 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/cyberInvest/message/648013012">said</a>, “Macau - China. I’d say that’s kinda global. And unstoppable.”<stembedurl>https://stocktwits.com/cyberInvest/message/648013012</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/cyberInvest/message/648034961">said</a>, “with NMPA - Macau - China approval apparent, FDA needs to get with it. This level of disfunction is a national embarrassment. China approves before US for a US company??? This is like a Saturday Night Live skit.”<stembedurl>https://stocktwits.com/cyberInvest/message/648034961</stembedurl>IBRX stock has more than tripled over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List 

IBRX Stock - Anktiva, an immunotherapy for bladder cancer, was listed in Macau’s March filing alongside globally approved drugs from major pharma players.

Anktiva, an immunotherapy for bladder cancer, was listed in Macau’s March filing alongside globally approved drugs from major pharma players.

ImmunityBio (NASDAQ:IBRX) Shares Up 3%  - Should You Buy?

ImmunityBio (NASDAQ:IBRX) Stock Price Up 3% - Here's Why...

ImmunityBio (NASDAQ:IBRX) Stock Price Up 4.3% - Here's Why

ImmunityBio (NASDAQ:IBRX) Shares Up 4.3% - Should You Buy...

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

With 132M shares short and 100% utilization, traders are betting on a massive, rapid breakout as trapped short sellers look for an exit.

Strategic partnership reports for local manufacturing in Riyadh signal significant international validation and revenue potential in the MENA region.

Investors are closely watching new federal cancer vaccine initiatives and potential federal funding that could drastically accelerate treatment adoption.

Recent regulatory approvals in Macau provide a critical beachhead for expansion into broader Asian markets and China.

Current Price	$8.77
Prev Close	$8.82
Open	$8.97
Dividend Yield	0.00%
50-Day Moving Average	$7.10
Beta	1.97
Avg. Volume	38.67M
PE Ratio	-21.73

52-Week High	$12.43
52-Week Low	$1.83
Market Capitalization	$8.71B
EPS (Annual)	-$0.382
Price to Book	-17.12
Revenue Per Employee	$163,947.90

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IBRX News

IBRXImmunityBio Inc